EP1200626A1 - Procedes d'amplification d'acides nucleiques - Google Patents

Procedes d'amplification d'acides nucleiques

Info

Publication number
EP1200626A1
EP1200626A1 EP00949747A EP00949747A EP1200626A1 EP 1200626 A1 EP1200626 A1 EP 1200626A1 EP 00949747 A EP00949747 A EP 00949747A EP 00949747 A EP00949747 A EP 00949747A EP 1200626 A1 EP1200626 A1 EP 1200626A1
Authority
EP
European Patent Office
Prior art keywords
probe
rna
sequence
molecule
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00949747A
Other languages
German (de)
English (en)
Inventor
John Scott Lloyd
Anthony Weston
Donald L. Cardy
Peter Marsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Biocell International Ltd
Original Assignee
Cytocell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytocell Ltd filed Critical Cytocell Ltd
Publication of EP1200626A1 publication Critical patent/EP1200626A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]

Definitions

  • This invention relates to nucleic acid probe molecules, methods involving use of the probe molecules, and kits comprising the probe molecules.
  • PCR polymerase chain reaction
  • US 4683195 and 4683202 A number of nucleic acid amplification processes are disclosed in the prior art.
  • One such process is the polymerase chain reaction (PCR) and is disclosed in US 4683195 and 4683202.
  • the PCR process is well known and widely used but is not suitable for all applications since the method has some drawbacks including the need for adjusting reaction temperatures alternately between intermediate (e.g. 50°C-55°C) and high (e.g. 90°C- 95 °C) temperatures involving repeated thermal cycling.
  • intermediate temperatures e.g. 50°C-55°C
  • the time scale required for multiple cycles of large temperature transitions to achieve amplification of a nucleic acid sequence and the occurrence of sequence errors in the amplified copies of the nucleic acid sequence is a major disadvantage as errors occur during multiple copying of long sequence tracts.
  • RNA polymerases Alternative nucleic acid amplification processes that utilize RNA polymerases are disclosed in WO 88/10315 (Siska Diagnostics), EP 329822 (Cangene) EP 373960 (Siska Diagnostics), US 5,554,516 (Gen-Probe Inc.), WO 89/01050 (Burg et al), WO 88/10315 (Gingeras et al), and EP 329822 (Organon Teknika), which latter document relates to a technique known as NASBA.
  • These amplification processes describe a cycling reaction comprising of alternate DNA and RNA synthesis.
  • RNA/DNA synthesis is achieved principally through the annealing of oligonucleotides adjacent to a specific DNA sequence whereby these oligonucleotides comprise a transcriptional promoter.
  • the RNA copies of the specific sequence so produced, or alternatively an input sample comprising a specific RNA sequence (US 5,554,516), are then copied as DNA strands using a nucleic acid primer and the RNA from the resulting DNA: RNA hybrid is either removed by denaturation (WO 88/10315) or removed with RNase H (EP 329822, EP 373960 & US 5,554,516). Two further amplification processes are disclosed, one thermal and one isothermal, in WO 93/06240.
  • Both the thermal and isothermal versions depend on the hybridisation of two nucleic acid probes of which regions are complementary to the target nucleic acid. Portions of the probes are capable of hybridising to the sequence of interest such that the probes are adjacent or substantially adjacent to one another, so as to enable complementary arm specific sequences of the first and second probes to become annealed to each other. Following annealing, chain extension of one of the probes is achieved by using part of the other probe as a template. Amplification of the extended probe is achieved by one of two means; in the thermal cycling version thermal separation of the extended first probe is carried out to allow hybridisation of a further probe, substantially complementary to part of the newly synthesised sequence of the extended first probe.
  • Extension of the further probe by use of an appropriate polymerase using the extended first probe as a template is achieved.
  • Thermal separation of the extended first and further probe products can act as a template for the extension of further first probe molecules and the extended first probe can act as a template for the extension of other further probe molecules.
  • primer extension of the first probe creates a functional RNA polymerase promoter that in the presence of a relevant RNA polymerase transcribes multiple copies of RNA.
  • the resulting RNA is further amplified as a result of the interaction of complementary DNA oligonucleotides containing further RNA polymerase promoter sequences, whereupon annealing and extension of the RNA on the DNA oligonucleotide leads to a further round of RNA.
  • This cyclical process generates large yields of RNA, detection of which can be achieved by a number of means.
  • the invention provides a probe molecule comprising single stranded nucleic acid; said probe comprising a single stranded sequence complementary to a target nucleic acid sequence; a single strand of an RNA polymerase promoter sequence; and a blocking moiety adjacent or substantially adjacent to the promoter sequence.
  • RNA polymerase promoter sequences are well known to those skilled in the art. Preferred promoter sequences are those recognised by bacteriophage polymerases, especially T3, T7 or SP6 polymerase. T3, T7 and SP6 promoter sequences are typically 17 bases long. To be fully functional, the promoter sequence must be present in double stranded form.
  • T7 polymerase An example of a double stranded promoter sequence recognised by T7 polymerase is: 5' GAA ATT AAT ACG ACT CAC TAT AGG GAG AGA GAG C 3'
  • the promoter sequence is underlined (the significance of the -5 and + 12 sequences is explained elsewhere).
  • the promoter sequence recognised by the T7 polymerase may be referred to as the T7 promoter.
  • several minor variants of the sequence are known to be recognised by T7 polymerase, and to act as functional promoters.
  • RNA polymerase promoter it is known in the prior art to provide single stranded probe molecules which comprise one strand of an RNA polymerase promoter. When combined with the complementary strand, a fully functional double stranded promoter is formed, which may then allow for RNA synthesis (transcription) using adjacent sequences downstream of the template strand of the promoter as template.
  • formation of the double stranded, functional promoter occurs only as a result (directly or indirectly) of the presence of a particular target nucleic acid sequence of interst, such that RNA synthesis is (directly or indirectly) indicative of the presence of the sequence of interest.
  • RNA synthesis may occur in the absence of the sequence of interest
  • the signal: noise ratio can be dramatically improved by inclusion in the single stranded probe molecule of a "blocking moiety" which is not recognised by an RNA polymerase, the blocking moiety being positioned adjacent, or substantially adjacent, to the RNA polymerase promoter sequence.
  • adjacent as used in the context of the invention, is intended to indicate that there are no nucleic acid bases between the blocking moiety and the promoter sequence. In practice, it will normally be preferred that the blocking moiety is not directly adjacent to the promoter (i.e. is placed “substantially adjacent”).
  • substantially adjacent as used in the context of the invention, is intended to indicate that there are between 1 and 50 nucleic acid bases between the blocking moiety and the promoter sequence, preferably between 1 and 40, more preferably between 1 and 30, and most preferably between 1 and 20 bases. In particular, the inventors have found that a spacing of about 12-15 bases between the promoter and the blocking moiety appears to confer optimum results, especially where blocking moiety comprises an alkylene moiety.
  • the accepted numbering convention is that, for the template strand, the most 3' base of the promoter (assuming the promoter sequence consists of 17 bases) is indicated as position -17. Accordingly, an adjacent blocking moiety, positioned 3' of the promoter on the template strand, would be at position -18, and a "substantially adjacent" blocking moiety could be positioned anywhere between position -19 to -68, with preferred positioning being between -19 to -38, more especially between position -22 and -35.
  • nucleic acid probe molecule comprises the template strand of the RNA promoter
  • the blocking moiety will be positioned 3' of the promoter.
  • probe molecule comprises the non-template strand of the promoter it will be preferred to position the blocking moiety 5' of the promoter.
  • the probe molecule comprises the template strand of the RNA promoter sequence, but this is not essential.
  • nucleic acid bases there are several nucleic acid bases between the promoter sequence and the blocking moiety.
  • sequence of at least some of the intervening nucleic acid bases will be arranged so as to optimise promoter activity of the functional double stranded promoter.
  • a "-5" sequence is preferably present.
  • the -5 sequence is a sequence of 5 bases immediately 5' of the template strand of the promoter sequence, which has been found to enhance promoter activity.
  • the optimum sequence of bases constituting the -5 sequence tends to vary for each polymerase. For T7 polymerase, the optimum -5 sequence is that shown in bold letters above on page 3.
  • the blocking moiety included in the probe may be any entity which is not recognised as suitable template by an RNA polymerase.
  • the blocking moiety is capable of insertion in synthetic oligonucleotides by incorporation of appropriate precursors (e.g. phosphoramidites) during in vitro synthesis of the oligonucleotide.
  • the blocking moiety is unable to form base pairs with nucleic acid, and is advantageously located other than at the extreme 5' or 3' terminus.
  • Preferred blocking moieties include alkylene, alkanol and alkyl residues, especially C 2 -C 20 alkyl, alkanol or alkylene, more preferably C 3 -C 10 alkyl, alkanol or alkylene. Particular examples include octanediol, propanediol, hexaethylene glycol, and propyl residues.
  • the nucleic acid probe molecule comprises a plurality of blocking moieties, which may be positioned adjacent each other in the probe, or may be separated by intervening nucleic acid bases.
  • the plurality of blocking moieties may be of the same chemical entity, or may be different.
  • the probe molecule of the invention may comprise DNA, RNA, PNA (peptide nucleic acid) or LNA (locked nucleic acid), or any combination thereof.
  • the single stranded promoter sequence will normally substantially consist of DNA, although a few (e.g. 1-3) bases may be of, for example, RNA, PNA or LNA and still allow for the formation of a functional promoter when the promoter sequence is hybridised with a complementary DNA sequence.
  • PNA is a synthetic nucleic acid analogue in which the sugar/phosphate backbone is replaced by a peptide-linked chain (typically of repeated N-(2-aminoethyl)-glycine units), to which the bases are joined by methylene carbonyl linkages.
  • PNA/DNA hybrids have high Tm values compared to double stranded DNA molecules, since in DNA the highly negatively-charged phosphate backbone causes electrostatic repulsion between the respective strands, whilst the backbone of PNA is uncharged.
  • Another characteristic of PNA is that a single base mis-match is, relatively speaking, more destabilizing than single base mis-match in heteroduplex DNA.
  • PNA is useful to include in probes for use in the present invention, as the resulting probes have greater specificity than probes consisting entirely of DNA. Synthesis and uses of PNA have been disclosed by, for example, Orum et al, (1993 Nucl. Acids Res. 21, 5332); Egholm et al, (1992 J. Am. Chem. Soc. 114, 1895); and Egholm et al, (1993 Nature 365, 566).
  • LNA is a synthetic nucleic acid analogue, incorporating "internally bridged" nucleoside analogues. Synthesis of LNA, and properties thereof, have been described by a number of authors: Nielson et al, (1997 J. Chem. Soc. Perkin Trans. 1, 3423); Koshkin et al, (1998 Tetrahedron Letters 39, 4381); Singh & Wengel (1998 Chem. Commun. 1247); and Singh et al, (1998 Chem. Commun. 455). As with PNA, LNA exhibits greater thermal stability when paired with DNA, than do conventional DNA/DNA heteroduplexes. However, LNA can be synthesised on conventional nucleic acid synthesising machines, whereas PNA cannot.
  • the probe molecule of the invention may also comprise, if desired, modified nucleic acid bases, such as inosine and the like.
  • modified nucleic acid bases such as inosine and the like.
  • the probe molecule which hybridises to a nucleic acid target comprises PNA and/or LNA.
  • the target to which the probe molecule hybridises will typically comprise RNA and/or DNA.
  • the target to which the probe hybridises may be the actual sequence of interest (e.g. a human or other gene, which may be a marker of genetic or infectious disease), present in a sample to be investigated.
  • the presence in a sample of the sequence of interest may lead (directly or indirectly) to the presence of a further nucleic acid sequence, which is the target to which the nucleic acid probe hybridises.
  • a sample such as a sample of body fluid from a human or animal subject, or from an environmental sample
  • a sequence of interest may lead to the synthesis of a further RNA or DNA target sequence, to which the nucleic acid probe of the invention hybridises, the target nucleic acid sequence being formed by an assay method such as that disclosed in WO 93/06240, WO 99/37805 or WO 99/37806, for example.
  • a nucleic acid probe molecule in accordance with the invention may comprise (in the direction 5' to 3'); a template portion to be transcribed into RNA; (optionally) a + 12" portion (a sequence of 12 bases immediately adjacent to the 5' end of the promoter, which serves to enhance promoter activity in a manner similar to the -5 sequence: a particular example of a + 12 sequence for the T7 polymerase is shown previously on page 3 in italic type; a promoter sequence; (optionally) a -5 sequence; and a portion complementary to the target; with the one or more blocking moieties typically positioned 3' of the -5 sequence, generally within the target-complementary portion of the probe.
  • sequence of the probe molecule will be selected so as to hybridise near the 3 ' end region of the target such that the 3' end of the target may be extended by an appropriate DNA polymerase, in the presence of deoxyribonucleotide triphosphates, using the probe as template.
  • This extension of the target creates a complementary strand for the single stranded promoter sequence present in the probe, such that a double stranded, functional RNA polymerase promoter is formed, which can then cause the formation of RNA (in the presence of an appropriate RNA polymerase and ribonucleotide triphosphates).
  • RNA species may be detected directly, or may in turn be hybridised to a further probe (comprising a single stranded RNA promoter) and extended, thereby creating a further double stranded RNA polymerase promoter which leads to synthesis of a further RNA species.
  • a further probe comprising a single stranded RNA promoter
  • the sequences of the probes may be selected such that the sequence of the further RNA species matches (at least in part) that of the original target, such that the further RNA species may hybridise to the original probe molecule, restarting the process and leading to an amplification cycle. Such a cycle may form the basis of an extremely sensitive detection assay.
  • the RNA species may be the subject of a "stepped" amplification, in which each RNA species produced hybridises to a respective probe, and can be extended to create a double stranded promoter, leading to the synthesis of a further RNA species.
  • the number of amplification steps may be as many as desired, leading (eventually) to considerable amplification of the original signal but without undergoing any cycling.
  • probes comprising blocking moieties which might be expected to interfere with the process.
  • the inventors have found that use of probes in accordance with the invention reduces the background signal (i.e. amount of RNA produced in the absence of target), thereby improving the assay system.
  • probe molecules in accordance with the invention may be usefully employed in an assay method of detecting a nucleic acid sequence of interest in a sample.
  • the invention provides a method of detecting a nucleic acid sequence of interest in a sample, the method comprising the steps of: contacting a nucleic acid probe molecule in accordance with the first aspect of the invention defined above with a nucleic acid target molecule, which target is the sequence of interest or is formed as a result of the presence in the sample of the sequence of interest; causing extension of the 3' end of the target using the probe as a template, thereby creating a functional double stranded RNA polymerase promoter; causing RNA synthesis from the RNA polymerase promoter, to create an RNA molecule; and detecting directly or indirectly the RNA molecule so produced.
  • the step of causing extension of the 3' end of the target will conveniently be performed by addition of deoxyribonucleotide triphosphates in the presence of a DNA polymerase (such as Klenow fragment, or Bst polymerase) and in a suitable reaction buffer.
  • a DNA polymerase such as Klenow fragment, or Bst polymerase
  • Suitable reaction conditions are well known to those skilled in the art.
  • the blocking moiety in addition to blocking RNA polymerase, will tend also to reduce non-specific interactions involving DNA polymerase. Accordingly it will normally be preferred that the probe hybridises to the target in such a manner that the DNA polymerase will not need to extend the target past a blocking moiety (which will therefore be present in that part of the probe which hybridises to the target, although it will be apparent that the blocking moiety itself will tend not to be capable of base pairing, and so will not be base paired with the target).
  • the step of causing RNA synthesis will typically be effected by causing to be present an RNA polymerase which recognises the RNA promoter, together with suitable ribonucleotide triphosphates.
  • Preferred polymerases are T3,T7 and SP6 polymerase.
  • RNA molecule produced may itself be detected (i.e. "direct detection") or, as explained above, may be used to form one or more further RNA molecules (conveniently by means of a cycling or stepped amplification procedure) which may be detected (“indirect detection”) by any desired means.
  • direct detection i.e. "direct detection”
  • further RNA molecules inveniently by means of a cycling or stepped amplification procedure
  • direct detection a great number of detection methods are known to those skilled in the art.
  • detection will involve use of a labelled binding partner (e.g. a PNA, LNA, DNA or RNA sequence which hybridises to the original or further RNA molecules), typically being labelled with an enzyme label (horseradish peroxidase or alkaline phosphatase are preferred) or a fluorophore, a radio label or a biochemical label.
  • newly -synthesised RNA could be detected in a conventional manner (e.g. by gel electrophoresis), with or without incorporation of labelled bases during the synthesis.
  • RNA could be captured at a solid surface (e.g. on a bead, or in a microtitre plate), and the captured molecule detected by hybridisation with a labelled nucleic acid probe (e.g. radio-labelled, or more preferably labelled with an enzyme, chromophore, fluorophore and the like).
  • a labelled nucleic acid probe e.g. radio-labelled, or more preferably labelled with an enzyme, chromophore, fluorophore and the like.
  • Preferred enzyme labels include horseradish peroxidase and alkaline phosphatae.
  • Molecular beacons are molecules with which a fluorescence signal may or may not be generated, depending on the confirmation of the molecule. Typically, one part of the molecule will comprise a fluorophore, and another part of the molecule will comprise a "quencher” to quench fluorescence from the the fluorophore.
  • the molecular beacon when the conformation of the molecule is such that the fluorophore and quencher are in close proximity, the molecular beacon does not fluoresce, but when the fluorophore and the quencher are relatively widely-separated, the molecule does fluoresce.
  • the molecular beacon conveniently comprises a nucleic acid molecule labelled with an appropriate fluorophore and quencher.
  • the conformation of the molecular beacon is by hybridisation to a nucleic acid, for example inducing looping out of parts of the molecular beacon.
  • the molecular beacon may initially be in a hair-pin type structure (stabilised by self-complementary base-pairing), which structure is altered by hybridisation, or by cleavage by an enzyme or ribozyme.
  • FRET Fluorescence Resonance Energy Transfer
  • DEFRET Delayed Fluorescence Energy Transfer
  • HTRF HTRF
  • a donor e.g. Europium
  • a protective cage cryptate
  • the acceptor molecule that has been developed for this system is a protein fluorophore, called XL665. This molecule is linked to the 3' end of a second probe. This system has been developed by Packard.
  • the newly-synthesised RNA before or after amplification, results in formation of a ribozyme, which can be detected by cleavage of a particular nucleic acid substrate sequence (e.g. cleavage of a fluorophore/quencher dual-labelled oligonucleotide).
  • the invention provides a kit for use in the method of the second aspect, the kit comprising one or more probe molecules in accordance with the first aspect of the invention, and packaging means.
  • the kit may optionally comprise one or more of the following: instructions for performing the method of the invention; buffers; a DNA polymerase; an RNA polymerase; dNTPs; rNTPs; and a labelled binding partner.
  • Figure 1 is a schematic representation of a blocking moiety, hexaethylene glycol, incorporated into a DNA probe in accordance with the invention
  • Figures 2, 3 and 6 are schematic representations of nucleic acid probes in accordance with the invention, Figures 2 and 6 illustrating preferred embodiments;
  • Figures 4 and 5 are schematic representations of a pair of nucleic acid probes in accordance with the invention, which may be used in an amplification cycle;
  • Figure 7 is a schematic representation of an amplification cycle utilising the probes illustrated in Figures 4 and 5;
  • Figures 8-12 and 14-16 are bar charts comparing the yield (in femtomoles of RNA) for various reactions using probes in accordance with the invention comprising a blocking moiety, with those comprising conventional probes without a blocking moiety; and
  • Figures 13a and 13b are schematic representations of reaction schemes.
  • Hexaethylene glycol (Hex) linkers as blockers of RNA polymerase single strand read through and other non-specific side reactions caused by DNA polymerase.
  • Hex linkers were incorporated between bases -52/-53, -41/-42 and -29/-30.
  • Hex linkers were incorporated at all three positions.
  • oligonucleotide probes were synthesised by phosphoramidite chemistry using an Applied Biosystems 380A synthesiser according to the manufacturer's instructions. Hex incorporation was accomplished by reaction of the growing chain with 18-dimethoxytrityl hexaethylene glycol, l-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite. Biotinylation of oligonucleotide probes was achieved by incorporation of a biotin phosphoramidite. Oligonucleotides functionalised with alkaline phosphatase were prepared using the manufacturer's proprietary method (Oswel). All oligonucleotides were HPLC purified using standard techniques.
  • T7 RNA polymerase buffer 40 mM Tris-HCl (pH 7.9), 6 mM MgCl 2 , 2 mM spermidine, 10 mM NaCl
  • T7 RNA polymerase Promega
  • 25 units 2 ⁇ l rNTP mix
  • Hybridisation was achieved in an assay mixture that contained 10 fmol of linear DNA template (probe 3, 4, 5, 6 or 7) and 10 fmol of RNA complementary to the 3' end of the linear template (prepared as described above); Bst DNA polymerase (New England Biolabs) (3' ⁇ 5' exo-, 4 units); 1 ⁇ l dNTP mix (Amersham Pharmacia Biotech) (2.5 mM of each dNTP: 2'-deoxyadenosine 5'-triphosphate (dATP), 2'-deoxythymidine 5'- triphosphate (dTTP), 2 '-deoxy guanosine 5'-triphosphate (dGTP) and 2 '-deoxy cytidine 5'- triphosphate (dCTP)); T7 RNA polymerase buffer (Promega); T7 RNA polymerase (25 units) and 2 ⁇ l rNTP mix (Amersham Pharmacia Biotech). The reaction volume was made up to 20 ⁇ l with R
  • the results are those obtained using a probe with a) no Hex; b) Hex between base -53/-54 (assuming the most 3' base of the promoter sequence is at position -17); c) hex between -41/-42; d) hex between base -29/-20; and e) probe with three hexs, one each between bases -53/-54, -41/-42 and -29/-30.
  • the numbers above the columns indicate the amplification factor (upper number) and signal: noise ratio (lower number) respectively. From the results it can be seen that background RNA was generated when the linear DNA templates only were reacted with T7 RNA polymerase and Bst DNA polymerase.
  • Probe 4 (Template, as Seq ID No. 5 but with Hex between bases -53/-54) 5'TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCGTTCTCTCTTCCTATAGTGAGT CGTATTAATTTCTGCCTCCTTGTCTCCGTTCTGGATATCACCCHGATGTGTCTCC C 3' phosphate
  • Probe 5 (Template, as Seq ID No. 5 but with Hex between bases -41/-42) 5'TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCGTTCTCTCTTCCTATAGTGAGT CGTATTAATTTCTGCCTCCTTGTCTCCGTTCHTGGATATCACCCGATGTGTCTCC C 3' phosphate
  • Probe 6 (Template, as Seq ID No. 5 but with Hex between bases -29/-30) 5 CGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCGTTCTCTCTTCCTATAGTGAGT CGTATTAATTTCTGCCTCCHTTGTCTCCGTTCTGGATATCACCCGATGTGTCTCC C 3' phosphate
  • Probe 7 (Template, as Seq ID No. 5 but with Hex in all 3 positions) 5'TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCGTTCTCTCTTCCTATAGTGAGT CGTATTAATTTCTGCCTCCHTTGTCTCCGTTCHTGGATATCACCCHGATGTGTCT CCC 3' phosphate
  • This example demonstrated the use of Hex linkers in the cycled amplification of RNA.
  • Two DNA templates were used. The first DNA template annealed RNAl, followed by extension by DNA polymerase and transcription of RNA2. The second template annealed RNA2 followed by extension by DNA polymerase and transcription of RNAl. Reactions were performed using two DNA templates without Hex linkers and with two DNA templates each containing three Hex linkers.
  • RNAl was prepared using 1 pmol of probes 1 and 2, T7 RNA polymerase buffer (Promega) ;T7 RNA polymerase (Promega) (25 units) and 2 ⁇ l rNTP mix (Amersham Pharmacia Biotech). The reaction volume was made up to 20 ⁇ l with RNase-firee distilled water. The mixture was incubated at 37°C for 3 hours. DNA (probes 1 and 2) was removed from the assay mixture using RNase-free Dnase (Ambion) (3 units DNase added per 20 ⁇ l assay mix, incubated at 37°C for 10 minutes and 90 °C for 3 minutes).
  • RNase-free Dnase Ambion
  • the reaction mixture contained 1 fmol of probe 3 (no Hexs) or probe 4 (three Hexs) and 1 fmol of RNA prepared as in 2.2 above. This RNA was complementary to the 3' end of probes 3 and 4; Bst DNA polymerase (New England Biolabs) (3' ⁇ 5' exo-minus, 4 units); 1 ⁇ l dNTP mix (Amersham Pharmacia Biotech); T7 RNA polymerase buffer; T7 RNA polymerase (25 units) and 2 ⁇ l rNTP mix. The reaction volume was made up to 20 ⁇ l with RNase-free distilled water. The mixture was incubated at 41 °C for 1 or 2 hours.
  • Figure 10 shows the RNA yield for test and control reactions (in pairs) for DNA template probes without hex blocking moieties (two left hand pairs of columns) or probes comprising hex moieties (right hand pairs of columns).
  • the experiment was performed with second DNA template (for the cycling amplification reaction) added after 1 hour or 2 hours' incubation as indicated.
  • the importance of Hexaethylene glycol linkers was demonstrated when performing cycled amplification with two DNA templates. If DNA templates were used without chemical linkers then although amplification did occur, the yield of RNA was poor and the signal: noise was low. With chemical linkers, however, the signal was increased and the signal: noise was also improved. This improves the amplification process and would lead to increased sensitivity in nucleic acid amplification assay.
  • Probe 4 (as Seq ID No. 10 but with Hexs between bases -29/-30, -41/-42 and -53/-54) 5'TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCGTTCTCTCTTCCTATAGTG AGTCGTATTAATTTCTGCCTGCHTTGTCTGCGTTCHTGGATATCACCCHGAATC GTCAGTCCC 3' phosphate
  • Probe 6 (as Seq ID No. 11 but with Hexs between bases -28/-29, -40/-41 and -53/-54)
  • Hexaethylene glycol (Hex) linker located between bases -31/-32 caused a reduction in background.
  • a Hex linker lowered the background using three different DNA templates.
  • RNA was prepared using T7 RNA polymerase buffer (Promega); T7 RNA polymerase (Promega) (25 units) and 2 ⁇ l rNTP mix (Amersham Pharmacia Biotech). The reaction volume was made up to 20 ⁇ l with RNase-free distilled water. The mixture was incubated at 37°C for 3 hours. DNA was removed from the assay mixture using RNase-free Dnase (Ambion) (3 units DNase added per 20 ⁇ l assay mix, incubated at 37 °C for 10 minutes and 90 °C for 3 minutes). RNAl A was transcribed using 1 pmol probes 1A and 2A; RNA2A was prepared using 1 pmol probes 2 A and 3 A; RNA3A was prepared using 1 pmol probes 2 A and 4A.
  • Hybridisation was achieved in an assay mixture that contained 10 fmol of linear DNA template and 10 fmol of RNA complementary to the 3' end of the linear template; Bst (New England Biolabs) (3' ⁇ 5' exo-, 4 units), Klenow (New England Biolabs) (3' ⁇ 5' exo-, 4 units) or Phi29 (Amersham Pharmacia Biotech) DNA polymerase (3' — » 5' exo-, 1 unit); 1 ⁇ l dNTP mix (Amersham Pharmacia Biotech); T7 RNA polymerase buffer; T7 RNA polymerase (25 units) and 2 ⁇ l rNTP mix (Amersham Pharmacia Biotech). The reaction volume was made up to 20 ⁇ l with RNase-free distilled water. Control reactions contained linear template without complementary RNA. The mixture was incubated at 41 °C for 3 hours.
  • Microtitre plates were then processed as described in previous examples. Results are presented in Figures 11a, l ib and l ie. Figures l la-llc use the same general notation as used in Figures 8-10.
  • Figures 11a to l ie there are 3 pairs of columns (i), (ii) and (iii), which indicate results obtained using Bst, Klenow or Phi 29 polymerase respectively.
  • the left hand pairs of columns indicates the results obtained using probes without hex moieties, and the right hand pairs of columns are results obtained using hex-containing probes.
  • Figure 11a shows the results of reactions using RNA 1A and probes 5A (no hex) or 6A (with hex).
  • Figure l ib shows the results of reactions using RNA2A and probes 7 A (no hex) or 8A (with hex).
  • Figure l ie shows the results of reactions using RNA 3A and probes 9 A (no hex) or 10A (with hex).
  • RNA2A Seq ID No. 13 5'GGAAGCGAGAACUCGGGUGAUAUCCAGAACGCAGACAAGCAGGCA 3'
  • RNA3A Seq ID No. 15 5'GGAAGAGACAACGCUGAGGCUUGAGAGGAGAGACCGGAAGACGA3' Probe 5A as Seq ID No. 5, Example 1
  • Probe 6A (as Seq ID No. 5 but with Hex between bases -31/-32)
  • Probe 8A (as Seq ID No. 16 but with Hex between bases -31/-32)
  • Probe 10A (as Seq ID No. 12 but with Hex between bases -31/-32) 5'TGCCTGCTTGTCTGCGTTCTGGATATCACCCGAGTTCTCGCTTCCTATAGTGA GTCGTATTAATTTCTCGTCTTCCHGGTCTCTCCTCTCAAGCCTCAGCGTTGTCTC TTCC 3'
  • Example 1 Capture Probe 1 as Seq ID No. 6, Example 1 Detection probe 1 as Seq ID No. 7, Example 1
  • oligonucleotide probes were synthesised as described previously.
  • Octanediol (Oct) was incorporated by reaction of the growing chain with 8-dimethoxytrityl octanediol, l-[(2- cyanoethyl)-(N,N-diisopropyl)] -phosphoramidite.
  • Propanediol (Pro) was incorporated by reaction of the growing chain with 3-dimethoxytrityl propanediol, l-[(2-cyanoethyl)-(N,N- diisopropyl)]-phosphoramidite. All oligonucleotides were HPLC purified using standard techniques.
  • RNAl was prepared using 100 fmol of probes 1 and 2, T7 RNA polymerase buffer (Promega); T7 RNA polymerase (Promega) (25 units) and 2 ⁇ l rNTP mix (Amersham Pharmacia Biotech). The reaction volume was made up to 20 ⁇ l with RNase-free distilled water. The mixture was incubated at 37° C for 3 hours.
  • the reaction mixture contained 10 fmol of probe 3, probe 4 or probe 5 and 10 fmol of RNAl transcribed using probes 1 and 2. This RNA was complementary to the 3' end of probes 3, 4 or 5; Bst DNA polymerase (New England Biolabs) (3' -» 5' exo-minus, 4 units); 1 ⁇ l dNTP mix (Amersham Pharmacia Biotech); T7 RNA polymerase buffer; T7 RNA polymerase (25 units) and 2 ⁇ l rNTP mix (Amersham Phrmacia Biotech). The reaction volume was made up to 20 ⁇ l with RNase-free distilled water. The mixture was incubated at 37 °C for 3 hours.
  • RNAl was prepared using 100 fmol of probes 1 and 2, T7 RNA polymerase buffer; T7 RNA polymerase (25 units) and 2 ⁇ l rNTP mix (Amersham Pharmacia Biotech). The reaction volume was made up to 20 ⁇ l with RNase-free distilled water. The mixture was incubated at 37° C for 3 hours.
  • Reaction mixtures contained 10 fmol of probe 2 and probe 3 or 10 fmol of probe 2 and probe 4.
  • Probe 2 was complementary to the -5 and T7 promoter sequences of probes 3 and 4 thereby creating a double stranded T7 promoter.
  • Reactions contained T7 RNA polymerase buffer (Promega); T7 RNA polymerase (Promega) (25 units) and 2 ⁇ l rNTP mix (Amersham Pharmacia Biotech). The reaction volume was made up to 20 ⁇ l with RNase-free distilled water. The mixture was incubated at 37 °C for 3 hours.
  • Reaction mixtures contained 10 fmol of RNAl and probe 3 or 10 fmol RNAl and probe 4; 10 fmol probe 5 and probe 6 or 10 fmol probe 7 and probe 6; 10 f ol probe 5 and probe 8 or 10 fmol probe 7 and probe 8.
  • the RNA or DNA primers (RNAl, probe 5 or probe 7) were complementary to the 3' ends of probes 3, 4, 6 and 8.
  • Each reaction contained Bst DNA polymerase (New England Biolabs) (3' ⁇ 5' exo-minus, 4 units); 1 ⁇ l dNTP mix (Amersham Pharmacia Biotech); T7 RNA polymerase buffer; T7 RNA polymerase (25 units) and 2 lrNTP mix.
  • the reaction volume was made up to 20 1 with RNase-free distilled water. The mixture was incubated at 37 °C for 3 hours.
  • RNA transcripts from probes 3 and 4 were quantified using capture probe 1 and detection probe 1; RNA transcripts from probes 6 and 8 were quantified using capture probe 2 and detection probe 2.
  • Results are presented in Figures 14 and 15.
  • Figure 14(a) shows the amount of RNA produced using probes 2 and 3 (left hand pair of columns) or probes 2 and 4 (right hand pair of columns), in a transcription-only reaction.
  • Figure 14(b) shows the amount of RNA produced in a reaction requiring extension, followed by transcription, using probe 3 and RNAl (left hand pair of columns) or probe 4 and RNA 1 (right hand pair of columns).
  • the left hand column shows the yield for the full reaction
  • the right hand column shows the yield for the control reaction.
  • a hex moiety was located downstream of the T7 promoter, as indicated in Figure 13(a).
  • Figure 15 shows the amount of RNA produced using a template without hex (a) or a template with hex (b).
  • a(i) shows the results using probes 5 and 6
  • a(ii) shows the results using probes 6 and 7
  • b(i) shows the results using probes 5 and 8
  • b(ii) shows the results using probes 7 and 8.
  • This example compared the stepped amplification of 50 amol of a DNA primer using two linear DNA templates either containing or not containing chemical linkers.
  • Hybridisation was achieved in an assay mixture that contained 1 fmol of probe 1 and 50 amol of a DNA primer (probe 2) complementary to the 3' end of the linear template (probe 1); Bst DNA polymerase (New England Biolabs) (3' ⁇ 5' exo-, 4 units); 1 ⁇ l dNTP mix (Amersham Pharmacia Biotech).
  • the reaction volume was made up to 18 ⁇ l with RNase- free distilled water. The mixture was incubated at 37 °C for 1 hour. After this time, 20 fmol probe 3 was added in a volume of 2 1, thus making the reaction volume 20 1.
  • probes 4 and 5 were used for reactions containing probes without chemical linkers. Control reactions contained probes 1 and 3 only or probes 4 and 5 only.
  • RNA yield in femtomoles
  • A blocking moiety in accordance with the invention
  • B used conventional template probes without a blocking moiety
  • All reactions used 1 fmol of first template, and either 20 or 40 fmol of second template, as indicated beneath the columns.
  • the numbers above the columns indicate the amplification factor (top number) and signal: noise ratio (bottom number).
  • the left hand column shows the result for the full reaction
  • the right hand column shows the results for the control reaction.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une molécule sonde renfermant un acide nucléique monocaténaire. Cette sonde renferme une séquence monocaténaire complémentaire à une séquence cible d'acide nucléique, un seul brin d'une séquence promotrice d'ARN polymérase, et une fraction bloquante adjacente ou sensiblement adjacente à la séquence promotrice. L'invention concerne également un procédé de détection d'une séquence d'acide nucléique d'intérêt au moyen de la sonde, ainsi que des kits comprenant la sonde.
EP00949747A 1999-07-29 2000-07-31 Procedes d'amplification d'acides nucleiques Withdrawn EP1200626A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9917816 1999-07-29
GBGB9917816.2A GB9917816D0 (en) 1999-07-29 1999-07-29 Chemically modified probes used to regulate nucleic acid amplification assays
PCT/GB2000/002946 WO2001009376A1 (fr) 1999-07-29 2000-07-31 Procedes d'amplification d'acides nucleiques

Publications (1)

Publication Number Publication Date
EP1200626A1 true EP1200626A1 (fr) 2002-05-02

Family

ID=10858162

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00949747A Withdrawn EP1200626A1 (fr) 1999-07-29 2000-07-31 Procedes d'amplification d'acides nucleiques

Country Status (6)

Country Link
EP (1) EP1200626A1 (fr)
JP (1) JP2003505107A (fr)
AU (1) AU6302000A (fr)
CA (1) CA2381958A1 (fr)
GB (1) GB9917816D0 (fr)
WO (1) WO2001009376A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121358A2 (fr) * 2004-06-10 2005-12-22 Exiqon A/S Sondes extensibles
WO2018174827A1 (fr) * 2017-03-24 2018-09-27 National University Of Singapore Procédés de détection multiplex de molécules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480784A (en) * 1989-07-11 1996-01-02 Gen-Probe Incorporated Nucleic acid sequence amplification methods
CA2118913C (fr) * 1991-09-13 2008-08-19 Donald Leonard Nicholas Cardy Essai d'extension d'acides nucleiques
AU681082B2 (en) * 1992-05-06 1997-08-21 Gen-Probe Incorporated Nucleic acid sequence amplification method, composition and kit
FR2726277B1 (fr) * 1994-10-28 1996-12-27 Bio Merieux Oligonucleotide utilisable comme amorce dans une methode d'amplification basee sur une replication avec deplacement de brin
AU752220B2 (en) * 1998-01-27 2002-09-12 British Biocell International Limited Modified nucleic acid probes and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0109376A1 *

Also Published As

Publication number Publication date
CA2381958A1 (fr) 2001-02-08
JP2003505107A (ja) 2003-02-12
AU6302000A (en) 2001-02-19
WO2001009376A1 (fr) 2001-02-08
GB9917816D0 (en) 1999-09-29

Similar Documents

Publication Publication Date Title
AU752220B2 (en) Modified nucleic acid probes and uses thereof
US7005261B1 (en) Method for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter
JP4646404B2 (ja) 分子トーチ（ｔｏｒｃｈ）
EP0876510B1 (fr) Amplification et detection homogenes des acides nucleiques
JP3085409B2 (ja) 標的核酸配列の検出方法およびそのための試薬キット
KR0161327B1 (ko) 핵산의 민감한 검출 방법
FI114992B (fi) Menetelmä kohdenukleiinihappojen osoittamiseksi
AU747140B2 (en) Method for detection of nucleic acid target sequences involving (in vitro) transcription from an RNA promoter
JP2004500850A5 (fr)
JPH10502259A (ja) 有機相中への抽出による疎水性増幅生成物の検出
EP1590482B1 (fr) Amplification d'acides nucleiques au moyen de bases non standard
JP2644419B2 (ja) 核酸の固定化
WO2003072721A2 (fr) Detection par glissement d'une amplification de matrice
EP1017855B1 (fr) Synthetisation de polynucleotides par ligature d'oligomeres multiples
WO2001009376A1 (fr) Procedes d'amplification d'acides nucleiques
JP2009511055A (ja) 標的核酸シグナル検出
AU779591B2 (en) Method for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter
WO2023108014A1 (fr) Procédés et compositions pour l'analyse d'acides nucléiques
CN117625768A (zh) 一种通用数字pcr检测体系及其应用
JP2005110664A (ja) 核酸シグナルの増幅による標的ｄｎａの存在を検出する方法、及び免疫学的配位子の検出又は定量する方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRITISH BIOCELL INTERNATIONAL LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060201